Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 17;10:15244. doi: 10.1038/s41598-020-72179-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Optimized dosage and route of TAM administration induces gradual increase in YFP expression over time. (A) Frequency and (B) MFI of YFP expression within peripheral blood CD45+ cells analyzed at different time points (n = 5). Different colors represent individual mice. Validation with another larger cohort of mice (n = 21) showing (C) frequency (Day 5—23.2 ± 6.1%, Day 14—25.2 ± 7.2%, Day 21—32.9 ± 8%, Day 32—40.7 ± 7.6%) and (D) MFI of YFP expression (Day 5—855.9 ± 89.7, Day 14—1,354.5 ± 337.3, Day 21—2,104.7 ± 275.6, Day 32—1875.9 ± 474.3) within peripheral blood CD45 + cells at different time points after the beginning of treatment. YFP MFI was measured on YFP+ cells. In both cohorts, mice were treated for 5 consecutive days with 3 mg of TAM administered PO. Mixed model ANOVA test with repetitive measures was performed to identify significant differences following 3 mg TAM treatment PO (A,B). Data are presented as mean ± SEM. Non-Paired T test for used for unpaired sample comparisons (C,D). ***p ≤ 0.001, ****p ≤ 0.0001.